SLC1A7

Across TCGA pan-cancer cohorts, SLC1A7 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated SLC1A7 data layer compared with 22 for mass-spec protein.

The strongest signal is observed in kidney chromophobe (KICH), where higher SLC1A7 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated SLC1A7 expression acts as an unfavorable survival marker, although some lineages such as SKCM and UCEC show a favorable association.

KICH, SKCM, and LGG are the cancer types where SLC1A7 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KICH	DFS	Median	All	0.102	0.848	.004	13	view →
SKCM	DFS	Median	All	0.844	0.727	.014	9	view →
LGG	OS	Median	All	0.173	0.799	<.001	6	view →
COAD	OS	Median	III,IV	0.157	0.791	.001	6	view →
BRCA	DFS	Median	All	0.134	0.527	.017	4	view →
UCEC	OS	Median	All	0.969	0.658	.024	4	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

SLC1A7–KICH (DFS)

Open the KICH breakdown →